Can Adults Get Roseola? Symptoms and What to Know

Adults can get infected with human herpesvirus 6 (HHV-6), the virus behind roseola, but it rarely looks like the classic childhood illness with its signature high fever and spreading rash. Nearly every adult already carries HHV-6 from a childhood infection, so “getting roseola” as an adult usually means the dormant virus has woken back up, not that a brand-new infection has occurred. When it does flare, symptoms range from barely noticeable to seriously dangerous, depending almost entirely on the state of your immune system.

Why the Classic Childhood Rash Is Rare in Adults

Roseola infantum, sometimes called “sixth disease,” is overwhelmingly a childhood event. Primary infection with HHV-6B happens in nearly all children, typically before age two.¹ By the time you reach adulthood, your immune system has already encountered the virus and built a response to it. That initial childhood infection usually plays out as a few days of high fever followed by a pinkish rash that appears once the fever breaks, though many children never develop the rash at all and the infection passes unnoticed.

Because the vast majority of adults were infected years ago, the pool of people who could experience a true first-time HHV-6 infection as an adult is extremely small. It does happen, though. A small number of adults reach adulthood without prior exposure, and when they catch HHV-6 for the first time, the illness tends not to resemble the classic baby rash. Instead, it can produce something closer to a mononucleosis-like illness, with prolonged fatigue, swollen lymph nodes, and fever.² That mononucleosis-like presentation is actually one of the recognized causes of “mono” in people who test negative for the Epstein-Barr virus that causes most cases of mono.³

The Difference Between a New Infection and Reactivation

When people talk about “getting roseola” as an adult, they almost always mean something different from what happens to a toddler. HHV-6 belongs to the herpesvirus family, which means it never fully leaves your body. After that initial childhood illness resolves, the virus parks itself inside certain cells and goes dormant. Most adults remain chronically infected, with the latent virus held in check by a healthy immune system.⁴ The virus can reactivate when immune surveillance dips, and that reactivation is what adults experience far more often than a fresh infection.

Reactivation in a person with a normal immune system is usually mild enough to go unrecognized. You might have a low-grade fever for a day or two, some fatigue, or nothing at all. The virus briefly replicates, the immune system stamps it back down, and life continues. Where things get serious is when the immune system is substantially weakened, either by disease, medication, or transplant protocols.

Who Faces the Greatest Risk

The adults most vulnerable to HHV-6 reactivation causing real harm are transplant recipients. People who undergo bone marrow transplants (formally called hematopoietic stem cell transplants) or solid organ transplants take powerful drugs to suppress their immune systems and prevent rejection. That suppression removes exactly the guardrails that keep HHV-6 dormant.⁴

In transplant recipients, HHV-6 reactivation can cause fever, skin rash, diarrhea, lung problems, delayed recovery of blood cell counts, and in the worst cases, inflammation of the brain.⁵ One study of bone marrow transplant patients who experienced early HHV-6 reactivation found that only about 5% had no symptoms at all. Fever, rash, and diarrhea were the most frequent problems, and severe complications including brain inflammation and lung disease occurred in a meaningful subset of patients.⁶ Research in recent years has also strengthened the connection between HHV-6B reactivation and graft-versus-host disease, a condition where the transplanted cells attack the recipient’s body.⁷

People living with untreated HIV, those on long-term immunosuppressive therapy for autoimmune diseases, and patients receiving chemotherapy for cancer also face elevated risk, though the transplant population is by far the most studied.

What Adult Symptoms Actually Look Like

If you are an otherwise healthy adult and HHV-6 reactivates, here is what you might notice:

• Fatigue: a few days of unusual tiredness, sometimes enough to make you think you are coming down with something
• Low fever: mild and short-lived, often without a clear explanation
• Faint rash: possible but uncommon, and it rarely has the dramatic head-to-trunk pattern seen in babies
• Sore throat and swollen glands: particularly if the presentation mimics mononucleosis

These symptoms overlap so heavily with dozens of other viral infections that HHV-6 reactivation in healthy adults almost never gets diagnosed. Most people chalk it up to a mild bug and move on. That is usually the right call, because in people with intact immune systems, the virus retreats to dormancy without medical intervention.

For immunocompromised adults, the symptom picture broadens considerably. Rash becomes more common and more pronounced, fevers run higher and longer, gastrointestinal problems are frequent, and the risk of organ involvement climbs. Lung inflammation and liver injury enter the picture, making HHV-6 reactivation a diagnosis that transplant teams actively monitor for.

Brain Inflammation and Neurological Complications

The most feared complication of HHV-6 reactivation in adults is encephalitis, or inflammation of the brain. After bone marrow transplant, HHV-6 encephalitis typically shows up as confusion, memory problems, and seizures, with brain imaging revealing characteristic damage to structures in the brain’s limbic system.⁸ It carries substantial risk of death and long-term neurological problems.⁹

What surprises many people is that HHV-6 encephalitis can occasionally strike adults with healthy immune systems. These cases are rare, but documented reports exist of otherwise-healthy people developing seizures and cognitive impairment from active HHV-6 replication in the brain. Research has suggested that HHV-6 can infect certain brain cells involved in regulating neural activity, potentially disrupting the balance of excitatory signaling in ways that trigger seizures.¹⁰ This remains uncommon enough that it catches even experienced physicians off guard, which can delay diagnosis.

The Connection to Drug Hypersensitivity Reactions

One of the more unexpected places HHV-6 shows up in adults is in DRESS syndrome, a severe drug reaction involving rash, fever, organ involvement, and elevated white blood cells. Viral reactivation has been recognized as part of this syndrome’s disease process, and HHV-6 is the most frequently implicated virus. In one study examining patients with DRESS, HHV-6 reactivation was detected in roughly 28% of the cases tested.¹¹ A case report illustrated how a 21-year-old with DRESS had HHV-6 detected in both blood and liver tissue, supporting the virus as a direct cause of the liver injury.¹²

The practical implication here is that if you develop a serious drug reaction with systemic symptoms, your medical team should consider HHV-6 reactivation as a contributing factor, not just the offending medication. It changes the treatment approach because addressing the viral component alongside stopping the drug can improve outcomes.

How HHV-6 Spreads, Even Among Adults

HHV-6 spreads primarily through saliva, and adults are highly efficient carriers. Studies using sensitive detection methods have found that somewhere between 85% and 95% of adults shed HHV-6B in their saliva.¹³ That means the virus is being passed around constantly through kissing, sharing utensils, and other normal close contact. Children pick it up from parents and older siblings, and the cycle continues generation after generation. Research on the related virus HHV-7, which can also cause roseola-like illness, has confirmed horizontal transmission flowing from grandparents to parents to children within the same household.¹⁴

There is no practical way to prevent HHV-6 transmission. No vaccine exists, the virus is ubiquitous, and the shedding rate among healthy adults is so high that avoidance is essentially impossible. For the overwhelming majority of people, this does not matter because primary infection in childhood is mild and the virus causes no ongoing problems. The transmission facts matter most for understanding why almost every adult has already been exposed.

Pregnancy and Reactivation

Pregnant adults sometimes worry about roseola exposure, particularly if they have a toddler at home with the illness. The reassuring news is that since nearly all adults are already seropositive, a fresh infection during pregnancy is extremely unlikely. Reactivation of the dormant virus, however, is surprisingly common during pregnancy. One study detected HHV-6 DNA in the blood of about 41% to 44% of pregnant women during months three through eight of pregnancy, compared with about 24% of age-matched non-pregnant women.¹⁵

Transfer of HHV-6 to the fetus appears to be uncommon. That same study found HHV-6 DNA in about 1% of cord blood samples, suggesting that while maternal reactivation is frequent, the virus crossing the placental barrier is a relatively rare event.¹⁵ The higher reactivation rate during pregnancy likely reflects the natural immune suppression that occurs to protect the developing fetus. For most pregnant women, this reactivation produces no symptoms and requires no treatment.

A Diagnostic Trap That Fools Blood Tests

About 1% of the population carries HHV-6 DNA permanently integrated into their own chromosomes, a condition called inherited chromosomally integrated HHV-6. This is not an active infection. The viral DNA was inserted into a human chromosome at some point in an ancestor’s history and has been passed down like any other genetic trait. The result is that every cell in the body carries a copy of the viral genome.

The problem is that standard blood tests for HHV-6 work by detecting viral DNA. When every cell in your body contains HHV-6 sequences, the test returns very high levels that can look identical to a raging active infection. High HHV-6 DNA levels in blood or spinal fluid from this inherited integration can mimic active infection, potentially leading to unnecessary antiviral treatment.¹⁶ Any diagnosis of HHV-6 encephalitis or other active central nervous system infection should not be made without first ruling out chromosomal integration by comparing DNA levels across different body fluids.¹⁷

This matters practically because a transplant recipient or a hospitalized patient with neurological symptoms might receive weeks of intravenous antiviral drugs based on test results that actually reflect a genetic quirk rather than active disease. Awareness of this phenomenon among clinicians has grown considerably in recent years, and diagnostic tools have improved, but misdiagnosis still occurs.⁷

How HHV-6 Is Treated in Adults

For healthy adults experiencing mild HHV-6 reactivation symptoms, no specific treatment is needed. Rest, fluids, and over-the-counter fever reducers handle the brief episode, and the immune system takes care of the virus on its own.

When treatment is necessary, typically in transplant recipients or people with encephalitis, intravenous antiviral drugs are used. Ganciclovir and foscarnet are both considered first-line agents because they are effective against HHV-6 and have shown positive clinical results. A review of HHV-6 encephalitis cases in adults with healthy immune systems found that most patients who received ganciclovir recovered fully. Of 14 patients given intravenous ganciclovir (sometimes followed by an oral antiviral), ten made a complete recovery, three had lingering neurological symptoms, and one died.¹⁸ Treatment guidelines for immunocompromised patients call for at least three weeks of intravenous antiviral therapy, while in people with normal immune function, about two weeks at full doses has been sufficient in most cases.¹⁸

HHV-6 and Chronic Fatigue

A more contested area of research involves the possible role of HHV-6 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The hypothesis is that repeated or persistent low-grade reactivation of HHV-6 might contribute to the crushing fatigue and other symptoms that define ME/CFS. Laboratory work has shown that when HHV-6 reactivates in cells, it triggers mitochondrial fragmentation and a broad inflammatory response that severely compromises how cells produce energy.¹⁹ That cellular picture matches what many ME/CFS patients experience subjectively: a body that cannot generate enough energy no matter how much they rest.

Other research has proposed that in a subset of ME/CFS patients, ongoing low-level viral protein release from HHV-6 and Epstein-Barr virus could chronically stimulate the immune system and impair the normal antibody response.²⁰ The evidence here is still largely based on cell studies and small patient groups rather than large clinical trials, so it is too early to call HHV-6 a proven cause of ME/CFS. But the biological plausibility is strong enough that researchers continue to investigate the connection, and some clinicians factor HHV-6 reactivation into their workup of patients with unexplained chronic fatigue.

HHV-7 and the Other Roseola Virus

HHV-6 gets the spotlight, but it is not the only virus that causes roseola. Human herpesvirus 7 (HHV-7) is a close relative that also infects nearly everyone during childhood and can produce the same fever-then-rash syndrome. HHV-7 has been associated with febrile illnesses, skin conditions, neurological problems, and complications in transplant patients.²¹ Despite that broad disease association, HHV-7 remains one of the least studied human herpesviruses. Much of what we know is confined to case reports rather than systematic studies. It spreads through saliva in the same way as HHV-6, passing within families from older to younger household members.¹⁴ For adults, the clinical implications mirror those of HHV-6: dormant carriage is the norm, reactivation is possible under immune stress, and serious complications are overwhelmingly concentrated in immunocompromised individuals.